Non-nucleoside reverse transcriptase inhibitors

US9718819B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Kenneth L. Arrington · Philadelphia, US
• Christopher S. Burgey · Philadelphia, US
• Robert Gilfillan · Scotland, GB
• Yongxin Han · Kirkland, CA
• Mehul Patel · Blue Bell, US
• Chun Sing Li · Shanghai, CN
• Yunfu Luo · Shanghai, CN
• Zhiyu Lei · Shanghai, CN

Key dates

• Filing date: Feb 1, 2016
• Grant date: Aug 1, 2017
• Expiry date: Feb 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I:are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.